Fut, nem toborozFázis nélkül
Evolve China PMCF Study
A legfontosabb adatok
- Ki végzi
- Stryker Neurovascular
- Hol
- Kína22 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 500 fő, tervezett
- Kezdés
- 2024. ápr. 24.
- Várható befejezés
- 2031. aug.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Surpass Evolve Flow Diverter System
- A regiszteradat frissítve
- 2026. március 30.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Subject age is ≥ 18 and ≤80 years
- Subject is eligible for Surpass Evolve FDS IFU, and/or physician intends to treat the subject with Surpass Evolve FDS per his/her judgement
- Subject, or subject's legally authorised representative (LAR) has provided signed informed consent using the Ethics Committee (EC)-approved consent form
- Subject is willing to comply with scheduled visits and examinations per institutional SOC
Ki nem vehet részt
- Subject has any non-target intracranial aneurysm treated within 30 days prior to study enrollment
- Subject has undergone previous treatment where it would interfere with the delivery and/ or placement and/or proper apposition of Surpass Evolve FDS
- Subject has acute target aneurysm rupture and/or subarachnoid hemorrhage occurred within 30 days prior to enrollment
- Antiplatelet and/or anticoagulation therapy (e.g. aspirin and clopidogrel) is contraindicated for the subject
- Female subjects who are pregnant/ nursing, or who are unwilling or unable to take adequate method of contraception prior to the 12-month study follow-up.*; *If the subject becomes pregnant during her participation, the physician will have to evaluate the risk associated to her continuing participation to the rest of the study
- Enrollment in another trial involving an investigational product and/or drug interfere with study procedure/ results
- Subject has any condition demonstrated as Warning or Precautions in IFU
- Subject with an active bacterial infection
- Subject in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as:; Severe intracranial vessel tortuosity or stenosis; and/or; Intracranial vasospasm not responsive to medical therapy
- Subject has not received dual anti-platelet agents prior to the procedure
- Subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study within 12 months post procedure
- The investigator determined that the health of the patient may be compromised by the patient's enrollment
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.
A vizsgált kezelések
- Surpass Evolve Flow Diverter System
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Post-Market Clinical Follow-up Study to Evaluate the Long-Term Safety and Effectiveness of Surpass Evolve Flow Diverter System
- A regiszteradat frissítve
- 2026. március 30.